Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Scientists develop human model of blood-brain barrier

In a first-of-its-kind development, a team of scientists created a lab model of the blood-brain barrier (BBB) surrounding the brain. The new model represents “a game-changing technology with broad implications for neuroscience, drug discovery, and personalized medicine,” Ziyuan Guo, PhD, assistant professor at the University of Cincinnati department of pediatrics…

Addressing anxiety may aid walking problems in Parkinson’s

People with Parkinson’s disease who have clinically significant anxiety tend to walk more slowly and with shorter steps than people with the disease who don’t have anxiety. That’s according to the study, “The impact of anxiety on gait impairments in Parkinson’s disease: insights from sensor-based gait analysis,” which…

AAN 2024: ND0612 improves Parkinson’s symptom control in trial

ND0612, a formation of levodopa/carbidopa administered continuously by an under-the-skin pump, led to better symptom control for people with advanced Parkinson’s disease in a Phase 3 trial, and the therapy’s efficacy and safety were consistent irrespective of patient factors like age, weight, and medication dosage. That’s according to…

AAN 2024: Prasinezumab may slow Parkinson’s symptom progression

Treatment with prasinezumab — an experimental therapy designed to stop toxic alpha-synuclein protein clumps from spreading through the brain — seems to slow the progression of motor symptoms in people with Parkinson’s disease. That’s according to the results of a new analysis that compared the findings of a…

AAN 2024: AskBio’s gene therapy seen to ease motor symptoms

AB-1005, an experimental gene therapy administered directly into the brain, helped ease motor symptoms in patients with moderate Parkinson’s disease, whereas it appeared to stabilize disease progression for those with mild disease in a small Phase 1 clinical trial. No serious safety issues were reported for the 11…